The Global Protein Therapeutics Market

Questions: Discounts, Updates etc.

Pages: 348

Price (Single): $2999

Price (Departmental): $4999

Price (Company): $6999

Publication Date: 2006-12-06

Order Online Now

Name:
Email:
Company Name:
Telephone:
Licence Type:
Payment Method:

People that purchased this report also purchased:

Contact LeadDiscovery

If you have questions about this report
To find out if you qualify for a discount
Want a more up to date version
Can't find a report that meets your needs

Search all reports

Overview

The global protein therapeutics market was valued at US$57 billion in 2005. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. Recombinant proteins are potentially advantageous in terms of higher efficacy and fewer side effects than other pharmaceutical products, as they can be more specifically targeted to the cause of the disease, rather than the treatment of its symptoms.

This report examines each of the protein therapeutics classes in turn, assessing the market potential, and encompassing main therapeutic areas to which they are applicable.

The following product classes are analyzed in this report:

erythropoietins (EPO)
interferons
interleukins
insulin
monoclonal antibodies
blood-clotting factors
colony-stimulating factors (CSFs)
growth hormones
plasminogen activators
reproductive hormones
therapeutic enzymes

The report assesses the overall protein therapeutics market, key classes, and the factors influencing their historical and future performance. The report provides an overview of key products in each category, comparing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category, by region and by leading players and their products. Moreover, the report examines the promise of new drugs in each class and research and development efforts aimed at improving their delivery.

Finally, the future performance of the protein therapeutics market as a whole is examined against the background of pricing, emerging generic competition and manufacturing issues, indicating the likely trends in the coming years, and identifying possible solutions for problematic issues.

Key Features of this report:

Overview of the protein therapeutics environment, including main therapeutic categories, drug delivery technologies and key players

In-depth analysis of different classes of protein therapeutics, including key drugs in major therapeutic areas, as well as their advantages and disadvantages

Comprehensive facts and figures for the protein therapeutics market, including main players and regional break-downs

Future trends in the protein therapeutics marketplace, shaped by medical and technological advances as well as demographic and epidemiological changes and industry needs

Outlook for the protein therapeutics market, including manufacturing considerations and research into new methods of protein delivery

Table of Contents
1 Methodology, Executive Summary and Overview
- 2 Challenges and Issues Facing the Therapeutic Protein Market
  - 2.1 Pricing
  - 2.2 Drug Delivery
    - 2.2.1 Parenteral Delivery: Still the Leading Delivery Route for Therapeutic Proteins
Case Study: Sustainable Release Injectable Technology
Case Study: Immunex (Amgen) and Their Enbrel Shortage
Case Study: Genentech
Case Study: Biogenerics - Novartis and Omnitrope
- 3 Erythropoietins
  - 3.1 Overview of Class
  - 3.2 How Do Erythropoietins Work?
  - 3.3 Therapeutic Applications for Erythropoietins
    - 3.3.1 Anemia
      - 3.3.1.1 Cancer Related Anemia
      - 3.3.1.2 Renal Anemia
  - 3.4 Currently Marketed Products in the Class
    - 3.4.1 Procrit/Eprex (epoetin alfa)
    - 3.4.2 Epogen (epoetin alfa)
    - 3.4.3 Aranesp (darbepoetin alfa)
    - 3.4.4 NeoRecormon/Epogin (epoetin beta)
    - 3.4.5 Espo (epoetin alfa)
    - 3.4.6 Clinical Comparisons Between Marketed Erythropoietins
  - 3.5 Market Analysis
    - 3.5.1 Commercial Market Size
    - 3.5.2 Market Share by Country/Region
    - 3.5.3 Market Share, by Product Sales
    - 3.5.4 Market Share by Company
  - 3.6 Key Emerging Erythropoietin Therapies
    - 3.6.1 Dynepo
    - 3.6.2 Mircera
  - 3.7 Market Outlook
    - 3.7.1 Drivers
    - 3.7.2 Restraints
    - 3.7.3 Financial Forecast
- 4 Interferons
  - 4.1 Overview of Class
  - 4.2 Therapeutic Uses for Interferons
    - 4.2.1 Multiple Sclerosis
    - 4.2.2 Hepatitis
    - 4.2.3 Leukemia
  - 4.3 Classes of Interferons
    - 4.3.1 Beta Interferons
      - 4.3.1.1 Avonex (interferon beta-1a)
      - 4.3.1.2 Rebif (interferon beta-1a)
      - 4.3.1.3 Betaferon/Betaseron (interferon beta-1b)
    - 4.3.2 Alpha Interferons
      - 4.3.2.1 Intron A (interferon alpha-2b)
      - 4.3.2.2 PEG Intron (peg interferon alpha-2b)
      - 4.3.2.3 Rebetron (interferon alpha-2b + ribavirin)
      - 4.3.2.4 Roferon-A (interferon alpha-2a)
      - 4.3.2.5 Alferon N (interferon alpha-n3)
      - 4.3.2.6 Pegasys (pegylated interferon alpha-2a)
      - 4.3.2.7 Infergen (interferon alfacon-1)
    - 4.3.3 Gamma interferons
      - 4.3.3.1 Actimmune
  - 4.4 Market Analysis
    - 4.4.1 Commercial Market Size
    - 4.4.2 Market Share by Country/Region
    - 4.4.3 Market Share by Product Sales
    - 4.4.4 Market Share by Company
  - 4.5 R&D Trends in the Interferon Class
    - 4.5.1 Albuferon-Alpha
    - 4.5.2 Tauferon
    - 4.5.3 Interferon gamma-1b
    - 4.5.4 Neoferon
    - 4.5.5 Low-Dose Oral Interferon Alpha
  - 4.6 Market Outlook
    - 4.6.1 Drivers
    - 4.6.2 Restraints
    - 4.6.3 Financial Forecasts
      - 4.6.3.1 Beta Interferon Financial Forecast
      - 4.6.3.2 Alpha Interferon Financial Forecast
      - 4.6.3.3 Gamma Interferon Financial Forecast
- 5 Insulins
  - 5.1 Overview of Class
  - 5.2 How Does Insulin Work?
  - 5.3 Therapeutic Applications
    - 5.3.1 Diabetes
  - 5.4 Epidemiology
  - 5.5 Key Products in Diabetes Treatment
    - 5.5.1 Rapid-acting
      - 5.5.1.1 NovoRapid/Novolog (insulin aspart)
      - 5.5.1.2 Humalog (insulin lispro)
      - 5.5.1.3 Apidra (insulin glulisine)
      - 5.5.1.4 NovoMix (insulin aspart mix)
    - 5.5.2 Exubera (inhaled insulin)
    - 5.5.3 Short-acting (regular) and intermediate-acting
      - 5.5.3.1 Novolin (insulin)
      - 5.5.3.2 Insuman
      - 5.5.3.3 Humulin (insulin)
    - 5.5.4 Long-acting
      - 5.5.4.1 Lantus (glargine insulin)
    - 5.5.5 Levemir (insulin determir)
    - 5.5.6 Iletin (insulin)
  - 5.6 New Delivery of Insulin Stimulating Sales
  - 5.7 R&D Trends
    - 5.7.1 NN304 (insulin detemir)
    - 5.7.2 AERx insulin Diabetes Management System (iDMS)
    - 5.7.3 AIR (inhaled insulin)
    - 5.7.4 MannKind (inhaled insulin)
    - 5.7.5 NN344
    - 5.7.6 NN5401
  - 5.8 Market Analysis
    - 5.8.1 Commercial Market Size
    - 5.8.2 Market Share by Insulin Class
    - 5.8.3 Market Share by Country/Region
    - 5.8.4 Market Share by Product Sales
    - 5.8.5 Market Share by Company
  - 5.9 Market Outlook
    - 5.9.1 Financial Forecast
    - 5.9.2 Drivers
    - 5.9.3 Restraints
- 6 Monoclonal Antibodies
  - 6.1 Overview of Class
  - 6.2 How do Monoclonal Antibodies Work?
  - 6.3 Therapeutic Applications for Monoclonal Antibodies
    - 6.3.1 Cancer
      - 6.3.1.1 Rituxan (rituxumab)
      - 6.3.1.2 Erbitux (cetuximab)
      - 6.3.1.3 Herceptin (trastuzumab)
      - 6.3.1.4 Avastin (bevacizumab)
      - 6.3.1.5 Bexxar (tositumomab)
      - 6.3.1.6 Mylotarg (gemtuzumab ozogamicin)
      - 6.3.1.7 Zevalin (ibritumomab tiuxetan)
    - 6.3.2 Autoimmune/Inflammatory Diseases
      - 6.3.2.1 Rheumatoid Arthritis
        
        6.3.2.1.1 Remicade (infliximab)
        
        6.3.2.1.2 Humira (adalimumab)
      - 6.3.2.2 Multiple Sclerosis
        
        6.3.2.2.1 Tysabri (natalizumab)
      - 6.3.2.3 Crohn’s Disease
        
        6.3.2.3.1 Remicade
      - 6.3.2.4 Psoriasis
        
        6.3.2.4.1 Raptiva (efalizumab)
      - 6.3.2.5 Asthma
        
        6.3.2.5.1 Xolair
    - 6.3.3 Age-Related Macular Degeneration (AMD)
      - 6.3.3.1 Lucentis (ranibizumab)
    - 6.3.4 Transplant Rejection
      - 6.3.4.1 Simulect (basiliximab)
      - 6.3.4.2 Orthoclone OKT-3 (muromonab CD3)
    - 6.3.5 Other Conditions
      - 6.3.5.1 Percutaneous coronary intervention (PCI)
        
        6.3.5.1.1 ReoPro (abciximab)
      - 6.3.5.2 Lower Respiratory Tract Disease
        
        6.3.5.2.1 Synagis (palivizumab)
  - 6.4 Market Analysis
    - 6.4.1 Commercial Market Size
    - 6.4.2 Segmentation by Therapeutic Category
      - 6.4.2.1 Cancer
      - 6.4.2.2 Autoimmune/Inflammatory
    - 6.4.3 Market Share by Country/Region
    - 6.4.4 Key Product Sales
    - 6.4.5 Market Share by Company
    - 6.4.6 Market Outlook
      - 6.4.6.1 Drivers
      - 6.4.6.2 Restraints
      - 6.4.6.3 Financial Forecast
  - 6.5 Emerging Monoclonal Antibody Therapies
    - 6.5.1 Herceptin (Line Extension)
    - 6.5.2 Cotara (TNT-1)
    - 6.5.3 Rencarex (WX-G250)
    - 6.5.4 Humira
    - 6.5.5 Rituxan
    - 6.5.6 Actemra (tocilizumab)
    - 6.5.7 Remicade
    - 6.5.8 Tysabri
    - 6.5.9 Segard
    - 6.5.10 Anti-C5 antibody
    - 6.5.11 Aurograb
- 7 Blood-Clotting Factors
  - 7.1 Overview of Class
  - 7.2 How do Blood-Clotting Factors Work?
  - 7.3 Therapeutic Applications for Blood-Clotting Factors
    - 7.3.1 Hemophilia
  - 7.4 Leading Blood-Clotting Factors on the Market
    - 7.4.1 NovoSeven (recombinant coagulation factor VIIa)
    - 7.4.2 Advate (antihemophilic factor (recombinant), plasma/albumin-free method)
    - 7.4.3 Alphanate
    - 7.4.4 Helixate FS
    - 7.4.5 Hemofil-M (Factor VIII)
    - 7.4.6 Humate-P (antihemophilic factor/von Willebrand factor complex)
    - 7.4.7 Koate HP and Koate DVI (human antihemophilic (human) factor VIII)
    - 7.4.8 Kogenate FS (recombinant factor VIII)
    - 7.4.9 Monarc-M
    - 7.4.10 Monoclate-P
    - 7.4.11 Recombinate
    - 7.4.12 ReFacto (recombinant factor VIII)
    - 7.4.13 AlphaNine SD
    - 7.4.14 Bebulin VH (factor IX complex)
    - 7.4.15 BeneFIX (recombinant factor IX)
    - 7.4.16 Konyne 80
    - 7.4.17 Mononine
    - 7.4.18 Profilnine SD (systemic factor IX)
    - 7.4.19 Proplex T (factor IX complex)
  - 7.5 Market Analysis
    - 7.5.1 Commercial Market Size
    - 7.5.2 Market Share by Country/Region
    - 7.5.3 Market Share by Product Sales
    - 7.5.4 Market Share by Company
    - 7.5.5 Market Outlook
      - 7.5.5.1 Drivers
      - 7.5.5.2 Restraints
  - 7.6 Emerging Blood-Clotting Factors
    - 7.6.1 Bayer
    - 7.6.2 Cell Genesys
    - 7.6.3 Avigen
    - 7.6.4 Novo Nordisk
    - 7.6.5 Immune Response Corporation
    - 7.6.6 Targeted Genetics
- 8 Colony-Stimulating Factors
  - 8.1 Overview of Class
  - 8.2 How Do Colony Stimulating Factors Work?
  - 8.3 Therapeutic Applications for Colony Stimulating Factors
    - 8.3.1 Chemotherapy-Induced Neutropenia
  - 8.4 Key Colony Stimulating Factors
    - 8.4.1 Neupogen (filgrastim)
    - 8.4.2 Neulasta (pegfilgrastim)
    - 8.4.3 Gran (filgrastim)
    - 8.4.4 Leukine (sargramostim)
    - 8.4.5 Neutrogin / Granocyte (lenograstim)
  - 8.5 Market Analysis
    - 8.5.1 Commercial Market Size
    - 8.5.2 Market Share by Country/Region
    - 8.5.3 Market Share by Product Sales
    - 8.5.4 Market Share by Company
  - 8.6 Market Outlook
    - 8.6.1 Drivers
    - 8.6.2 Restraints
    - 8.6.3 Financial Forecast
  - 8.7 Emerging Colony-Stimulating Factors
    - 8.7.1 New Indications for Leukine (sargramostim)
    - 8.7.2 Longer-acting GM-CSFs
    - 8.7.3 PEGylated G-CSFs
    - 8.7.4 Maxy-G34
- 9 Human Growth Hormones
  - 9.1 Overview of Class
  - 9.2 How Do Growth Hormones Work?
  - 9.3 Therapeutic Applications for Growth Hormones
  - 9.4 Key Growth Hormones
    - 9.4.1 Genotropin (recombinant somatropin)
    - 9.4.2 Nutropin/Protropin (recombinant somatropin/somatrem)
    - 9.4.3 Norditropin/Norditropin SimpleXx (recombinant somatropin)
    - 9.4.4 Humatrope (recombinant somatropin)
    - 9.4.5 Geref (sermorelin acetate)
    - 9.4.6 Somatuline (lanreotide)
    - 9.4.7 Saizen (somatropin)
    - 9.4.8 Serostim (recombinant somatropin)
    - 9.4.9 Somavert (pegvisomant)
    - 9.4.10 Sandostatin (octreotride) and Sandostatin LAR (octreotide for injectable suspension)
  - 9.5 Expected Launches of Growth Hormones
    - 9.5.1 Valtropin (somatropin)
    - 9.5.2 Omnitrope (somatropin)
  - 9.6 Market Analysis
    - 9.6.1 Commercial Market Size
    - 9.6.2 Segmentation by Therapeutic Category
    - 9.6.3 Market Share by Country/Region
    - 9.6.4 Market Share by Product Sales
    - 9.6.5 Market Share by Company
  - 9.7 Market Outlook
    - 9.7.1 Drivers
    - 9.7.2 Restraints
  - 9.8 Emerging Human Growth Hormones
    - 9.8.1 Serostim (Serono)
    - 9.8.2 SomatoKine (Insmed Incorporated)
    - 9.8.3 Octreotide (QLT)
    - 9.8.4 ALX1-11 (NPS Pharmaceuticals)
    - 9.8.5 Geref (Serono)
    - 9.8.6 Leptin (Amgen)
    - 9.8.7 hGH (SkyePharma)
    - 9.8.8 hGHD-1 (Macromed)
- 10 Interleukins
  - 10.1 Overview of Class
  - 10.2 How Do Interleukins Work?
  - 10.3 Types of Interleukins and Their Functions
  - 10.4 Therapeutic Applications for Interleukins
    - 10.4.1 Cancer
    - 10.4.2 Human immunodeficiency virus (HIV)
    - 10.4.3 Transplantation
  - 10.5 Key Interleukin Products on Market
    - 10.5.1 Interleukin-1
    - 10.5.2 Interleukin-2
      - 10.5.2.1 Proleukin (aldesleukin)
      - 10.5.2.2 Ontak (denileukin deftitox)
      - 10.5.2.3 Imunace (celmoleukin)
    - 10.5.3 Interleukin 11
      - 10.5.3.1 Neumega (oprelvekin)
  - 10.6 Market Analysis
    - 10.6.1 Commercial Market Size
    - 10.6.2 Segmentation by Therapeutic Category
    - 10.6.3 Market Share by Country/Region
    - 10.6.4 Market Share by Product Sales
    - 10.6.5 Market Share by Company
  - 10.7 Market Outlook
    - 10.7.1 Drivers
    - 10.7.2 Restraints
  - 10.8 Emerging Interleukins
    - 10.8.1 IL-11 - Neumega (oprelvekin)
    - 10.8.2 New Indication for Proleukin (aldesleukin)
    - 10.8.3 Interleukin-12
    - 10.8.4 Cytoryn (IL-2 controlled release injectable depot)
    - 10.8.5 Interleukin-6 (Sigosix)
    - 10.8.6 Interleukin-4
    - 10.8.7 Interleukin-1
    - 10.8.8 Recombinant IL-10
    - 10.8.9 Prestara
- 11 Plasminogen Activators
  - 11.1 Overview of Class
  - 11.2 How Do Plasminogen Activators Work?
  - 11.3 Therapeutic Applications for Plasminogen Activators
    - 11.3.1 Heart Attack
    - 11.3.2 Stroke
    - 11.3.3 Pulmonary Embolism
  - 11.4 Key Plasminogen Activators on Market
    - 11.4.1 Activase (alteplase)
    - 11.4.2 Actilyse (alteplase)
    - 11.4.3 Abbokinase (urokinase)
    - 11.4.4 Rapilysin/Retavase (reteplase)
    - 11.4.5 TNKase (tenecteplase)
    - 11.4.6 Metalyse (tenecteplase)
    - 11.4.7 Streptase (streptokinase)
  - 11.5 Market Analysis
    - 11.5.1 Commercial Market Size
    - 11.5.2 Segmentation by Therapeutic Category
    - 11.5.3 Market Share by Country/Region
    - 11.5.4 Market Share by Product Sales
    - 11.5.5 Market Share by Company
  - 11.6 Market Outlook
    - 11.6.1 Drivers
    - 11.6.2 Restraints
  - 11.7 Emerging Plasminogen Activators
    - 11.7.1 Solinase (pamiteplase)
    - 11.7.2 Alfimeprase
    - 11.7.3 Lanoteplase
- 12 Reproductive Hormones
  - 12.1 Overview of Class
  - 12.2 How do Reproductive Hormones Work?
  - 12.3 Therapeutic Applications for Reproductive Hormones
    - 12.3.1 Osteoporosis
    - 12.3.2 Cancer
    - 12.3.3 Menopause-Related Conditions
    - 12.3.4 Male Sexual Dysfunctions
    - 12.3.5 Infertility
    - 12.3.6 Contraception
  - 12.4 Leading Reproductive Hormones on the Market
    - 12.4.1 Gonadotropins
    - 12.4.2 Hormone Replacement Therapy
    - 12.4.3 Estrogens and Progestins
  - 12.5 Market Analysis
    - 12.5.1 Commercial Market Size
    - 12.5.2 Segmentation by Therapeutic Category
    - 12.5.3 Market Share by Country/Region
    - 12.5.4 Market Share by Product Sales
    - 12.5.5 Market Share by Company
  - 12.6 Market Outlook
    - 12.6.1 Drivers
    - 12.6.2 Restraints
  - 12.7 Emerging Reproductive Hormones
- 13 Enzyme Replacement
  - 13.1 Overview of Class
  - 13.2 How does Enzyme Replacement Work?
  - 13.3 Therapeutic Applications for Enzyme Replacement
    - 13.3.1 Lysosomal storage disorders
    - 13.3.2 Fabry Disease
    - 13.3.3 Gaucher Disease
    - 13.3.4 Mucopolysaccharidoses (MPSs)
    - 13.3.5 Infantile Pompe Disease (IPD)
  - 13.4 Leading Enzyme Replacement Therapies on the Market
    - 13.4.1 Fabrazyme (agalsidase beta)
    - 13.4.2 Ceredase (alglucerase)
    - 13.4.3 Cerezyme (imiglucerase)
    - 13.4.4 Myozyme (alglucosidase alfa)
    - 13.4.5 Elaprase (idursulfase)
    - 13.4.6 Naglazyme (galsulfase)
    - 13.4.7 Aldurazyme (laronidase)
  - 13.5 Market Analysis
    - 13.5.1 Commercial Market Size
    - 13.5.2 Segmentation by Therapeutic Category
    - 13.5.3 Market Share by Country/Region
    - 13.5.4 Market Share by Product Sales
    - 13.5.5 Market Share by Company
  - 13.6 Market Outlook
    - 13.6.1 Drivers
    - 13.6.2 Restraints
  - 13.7 Emerging Enzyme Replacement Therapies
    - 13.7.1 AGT-180
    - 13.7.2 Phex
    - 13.7.3 ENZAGAL
    - 13.7.4 rhASB
- 14 Company Profiles
  - 14.1 Abbott Laboratories
  - 14.2 Amgen
  - 14.3 Amylin Pharmaceuticals
  - 14.4 Anika Therapeutics
  - 14.5 ArmaGen Technologies
  - 14.6 Biogen Idec
  - 14.7 BioMarin Pharmaceutical
  - 14.8 BioMimetic Therapeutics
  - 14.9 Bolder BioTechnology
  - 14.10 Boston Life Sciences
  - 14.11 Cambrex
  - 14.12 Cambridge Antibody Technology
  - 14.13 Ceregene
  - 14.14 Chiron Corporation
  - 14.15 Chugai Pharmaceutical
  - 14.16 Coley Pharmaceutical Group
  - 14.17 CuraGen
  - 14.18 Curis Inc
  - 14.19 Dragon Pharmaceuticals
  - 14.20 Enobia
  - 14.21 Enzon
  - 14.22 Eyetech Pharmaceuticals
  - 14.23 FibroGen
  - 14.24 FzioMed
  - 14.25 GeneMedix
  - 14.26 Genentech
  - 14.27 Genmab
  - 14.28 GenSci Regeneration Sciences
  - 14.29 Genvec
  - 14.30 Genzyme
  - 14.31 Human Genome Sciences
  - 14.32 ImClone Systems
  - 14.33 Insmed
  - 14.34 Janssen-Ortho
  - 14.35 Johnson & Johnson
  - 14.36 Maxygen
  - 14.37 Medarex
  - 14.38 MedImmune
  - 14.39 OSI Pharmaceuticals
  - 14.40 PeproTech
  - 14.41 PDL Biopharma
  - 14.42 Protein Polymer Technology
  - 14.43 Raven Biotechnologies
  - 14.44 Regeneron Pharmaceuticals
  - 14.45 Rentschler Biotechnologie
  - 14.46 Roche
  - 14.47 Sangamo Biosciences
  - 14.48 Scil Proteins
  - 14.49 Serono
  - 14.50 Spectrum Pharmaceuticals
  - 14.51 Seattle Genetics
  - 14.52 Stryker Biotech
  - 14.53 Theratechnologies
  - 14.54 Transition Therapeutics
  - 14.55 Vernalis Pharmaceuticals
  - 14.56 Wockhardt
  - 14.57 Wyeth
  - 14.58 Xoma
  - 14.59 ZymoGenetics
Tables
Table 1.1 Key Therapeutic Applications by Protein Class
Table 1.2 Leading Product Classes in Protein Therapeutics
Table 1.3 Leading Products in the Protein Therapeutics Market
Table 1.4 Leading 20 Companies in Protein Therapeutics by 2005 Sales
Table 2.1 Main Types of Drug Delivery by Injection (Parenteral Administration)
Table 2.2 Advantages of Injectable Drug Delivery Systems
Table 2.3 Key Companies in the Needleless Drug Technology Market
Table 2.4 Companies Involved in the Field of Transgenic Protein Technology
Table 2.5 Main Methods of Creating Transgenic Animals
Table 2.6 Advantages of Avian Transgenic Technology in Protein Manufacture
Table 2.7 Pros and Cons of Transgenic Plants
Table 3.1 Advantages and Disadvantage of Erythropoietin Therapy
Table 3.2 Global Sales of Erythropoietins 1999-2005
Table 3.3 US Sales of Erythropoietins 1999-2005
Table 3.4 Non-US Sales of Erythropoietins 1999-2005
Table 3.5 Erythropoietin Financial Forecast 2005-2011
Table 4.1 Major Types of MS
Table 4.2 Major Types of Leukemia
Table 4.3 Types of Leukemia Treatments
Table 4.4 Leading MS Therapy Delivery Routes and Dosage
Table 4.5 Global Sales of Beta Interferons 2000-2005
Table 4.6 US Sales of Beta Interferons 2000-2005
Table 4.7 Non-US Sales of Beta Interferons 2000-2005
Table 4.8 Global Sales of Alpha Interferons 2000-2005
Table 4.9 Global Sales of Gamma Interferons 2000-2005
Table 4.10 Forecast Sales of Avonex
Table 4.11 Forecast Sales of Betaseron
Table 4.12 Forecast Sales of Rebif
Table 4.13 Forecast Sales of PEG-Intron
Table 4.14 Forecast Sales of Intron
Table 4.15 Forecast Sales of Pegasys
Table 4.16 Forecast Sales of Actimmune
Table 5.1 Other Types of Diabetes
Table 5.2 Treatment of Types II Diabetes
Table 5.3 Estimated Number of People with Diabetes
Table 5.4 Types of Insulin
Table 5.5 Relationship of A1C to Average Whole Blood and Plasma Glucose Levels
Table 5.6 Patch Insulin
Table 5.7 Oral Spray Insulin
Table 5.8 Pulmonary Insulin
Table 5.9 Insulin Product Sales (US$mn)
Table 5.10 Forecast Insulin Product Sales
Table 5.11 Financial Forecast for the Insulin Market
Table 6.1 Monoclonal Antibody Therapies on the Market 2006
Table 6.2 Types of Cancer
Table 6.3 Types of Transplant Rejection
Table 6.4 Antibodies Used to Prevent Transplant Rejection
Table 6.5 Leading Monoclonal Antibody Products, by Sales 2000-2005
Table 6.6 Global Sales of Monoclonal Antibodies, Cancer Indications 2003-2005
Table 6.7 Global Sales of Monoclonal Antibodies, Autoimmune/Inflammatory Indications, 1999-2005
Table 6.8 Monoclonal Antibody Sales Market Share (2005), by Country/Region
Table 6.9 Global Sales of Remicade 2000-2005
Table 6.10 Global Sales of Rituxan 2000-2005
Table 6.11 Global Sales of Herceptin 2000-2005
Table 6.12 Global Sales of Humira 2003-2005
Table 6.13 Global Sales of Avastin 2004-2005
Table 6.14 Financial Forecast for the Monoclonal Antibody Market
Table 6.15 Emerging Monoclonal Antibody Therapies
Table 6.16 Types of ACR Response Criteria
Table 7.1 Overview of Blood-Clotting Factors and Their Function
Table 7.2 Leading Blood-Clotting Factors
Table 7.3 Competing Antihemophilic Factor Brands
Table 7.4 Key Blood Clotting Factors Product Sales (US$mn)
Table 7.5 Forecast Sales of Blood Clotting Factors (US$bn)
Table 8.1 Global Sales of Neupogen 1999-2005
Table 8.2 Global Sales of Neulasta 2002-2005
Table 8.3 Forecast Sales of Neulasta
Table 8.4 Forecast Sales of Neupogen
Table 8.5 Forecast Sales of Colony Stimulating Factors (US$bn)
Table 9.1 Effects of Human Growth Hormone
Table 9.2 Therapeutic Applications for Growth Hormones
Table 9.3 Different Indications for Genotropin
Table 9.4 GH Suppression during Long-Term Treatment with Immediate Release Sandostatin
Injection and Sandostatin LAR Depot
Table 9.5 Global Sales of Key Growth Hormone Products (US$mn)
Table 9.6 Key Company Involvement in hGH Delivery Technology
Table 9.7 Forecast Sales of Growth Hormones (US$bn)
Table 10.1 Interleukins, Major Sources and Effects
Table 10.2 Global Sales of Key Interleukins
Table 10.3 Forecast Sales of Interleukins (US$mn)
Table 11.1 Embolism and Its Outcomes
Table 11.2 Brand Names of PAs
Table 11.3 Forecast Sales of Plasminogen Activators
Table 12.1 Overview of Reproductive Hormones
Table 12.2 Reproductive Hormones and Their Therapeutic Applications
Table 12.3 FDA-Approved Bisphosphonates for the Treatment of Osteoporosis in Post-Menopausal Women
Table 12.4 Incidence and Death Rates of Cancer in the US (Male and Female)
Table 12.5 Hormone Therapy Regimes
Table 12.6 Medications for the Treatment of Infertility
Table 12.7 FDA-Approved Estrogens/Hormones for the Treatment of Osteoporosis
Table 12.8 Sales of Key Gonadotropins in US 2003-2005 (US$mn)
Table 12.9 Global Sales of Key HRT Products in US$mn (2003-2005)
Table 12.10 Global Sales of Johnson & Johnson’s Hormonal Contraceptives in US$mn (2003-2005)
Table 12.11 Global Sales of Schering AG’s Hormonal Contraceptives in US$mn (2004-2005)
Table 12.12 Forecast Sales of Reproductive Hormones
Table 13.1 Types of Mucopolysaccharidosis
Table 13.2 Global Sales of Key Enzyme Replacement Products
Table 13.3 Key Companies Involved in the ERT Market
Table 14.1 Biogen Idec’s Oncology Pipeline
Table 14.2 Chiron’s Oncology Pipeline
Table 14.3 Chugai’s Oncology Pipeline
Table 14.4 Enzon Drug Delivery Portfolio, 2006
Table 14.7 Wockhardt’s Biopharmaceutical Pipeline
Table 14.5 Medarex’s Oncology Pipeline
Graphs
Graph 1.1 Market Share of Product Classes in Protein Therapeutics
Graph 1.2 Percentage Change in the 2005-2010 Sales of Protein Therapeutics by Class
Graph 1.3 Leading 10 Products in the Protein Therapeutics Market by 2005 Sales
Graph 1.4 Protein Therapeutics Market Share by Company
Graph 3.1 Sales of Erythropoietin Products 1999-2005, US & Rest of World
Graph 3.2 Percentage Growth of Erythropoietin Products, 2004-2005
Graph 3.3 Market Share Erythropoietin Products, US vs Rest of World 2005
Graph 3.4 Market Share Erythropoietin Products, US vs Rest of World 2004
Graph 3.5 Market Share, Erythropoietin Products 2005
Graph 3.6 Market Share, Erythropoietin Products 2004
Graph 3.7 Company Market Share, Erythropoietin Products 2005
Graph 3.8 Company Market Share, Erythropoietin Products 2004
Graph 4.1 2005 Sales of Leading MS Therapies
Graph 4.2 Country/Region Market Share Beta Interferons 2005
Graph 4.3 Market Share Beta Interferons 2005
Graph 4.4 Market Share Alpha Interferons 2005
Graph 4.5 Company Market Share, Beta Interferons 2005
Graph 4.6 Company Market Share Alpha Interferons 2005
Graph 5.1 Insulin Sales Segmentation by Drug Class
Graph 5.2 Insulin Market by Country/Region
Graph 5.3 Humulin Sales by Geographical Region (2005)
Graph 5.4 Humalog Sales by Geographical Region (2005)
Graph 5.5 Insulin Market Share by Product (2005)
Graph 5.6 Insulin Market Share by Company
Graph 5.7 Product Sales Percentage Change 2005-2010*
Graph 5.8 Forecast Growth of the Insulin Market (2005-2010)
Graph 6.1 Leading Monoclonal Antibody Products by 2005 Sales
Graph 6.2 Monoclonal Antibody Market by Therapeutic Category (2005)
Graph 6.3 Annual Growth of Global Monoclonal Antibody Market, Cancer Indications 2003-2005
Graph 6.4 Annual Growth of Global Monoclonal Antibody Market, Autoimmune/Inflammatory Indications,
- 1999-2005
Graph 6.5 Monoclonal Antibody Sales Market Share by Three Key Regions
Graph 6.6 Monoclonal Antibody Market Share, by Top Five Products
Graph 6.11 Leaders in the Monoclonal Antibody Therapy Market, 2005 Market Share
Graph 7.1 Blood Clotting Market Share by Country/Region
Graph 7.2 Blood Clotting Market Share by Factor
Graph 7.3 Blood Clotting Market Share by Company
Graph 7.4 Forecast Annual Growth of Blood Clotting Factors
Graph 8.1 CSF Market by Country/Region
Graph 8.2 Global Sales of Neupogen and Neulasta 2002-2005
Graph 8.3 Global CSF Market by Product (2005)
Graph 8.4 Global CSF Market by Company (2005)
Graph 8.5 Forecast Annual Sales Growth of the CSF Market
Graph 9.1 HGH Market Segmentation by Therapeutic Application
Graph 9.2 HGH Market by Region (2005)
Graph 9.3 Growth Hormone Market Share by Company
Graph 9.4 Forecast Annual Growth of Growth Hormones
Graph 10.1 Interleukin Market Segmentation by Therapeutic Category
Graph 10.2 Interleukin Market Segmentation by Country/Region
Graph 10.3 Interleukins Market by Product Sales
Graph 10.4 Market Share by Company
Graph 10.5 Forecast Annual Sales Growth of Interleukins
Graph 11.1 Plasminogen Activators Market Share by Therapeutic Application
Graph 11.2 Plasminogen Activators Market Segmentation by Country/Region
Graph 11.3 Plasminogen Activators Market Share by Product Sales
Graph 11.4 Global Sales of Genentech’s PAs (US$mn)*
Graph 11.5 Plasminogen Activators Market Share by Company
Graph 11.6 Forecast Annual Sales Growth of Plasminogen Activators
Graph 12.1 Segmentation of Hormone Replacement Market by Therapeutic Category
Graph 12.2 Reproductive Hormones Market Segmentation by Country/Region
Graph 12.3 Global Sales of Key Gonadotropins
Graph 12.4 Annual Growth of HRT Product Sales
Graph 12.5 Forecast Annual Sales Growth of Reproductive Hormones
Graph 13.1 ERT Market Segmentation by Therapeutic Category
Graph 13.2 ERT Market Segmentation by Country/Region
Graph 13.3 Global Sales of Key Enzyme Replacement Products
Graph 13.4 ERT Market by Company
Figures
Figure 12.1 Simplified Graphic Representation of Normal Gonadal Function

Other users found this report page using the following search terms: protein Therapeutics Monoclonal Antibodies Recombinant market global cost insuman efficacy therapeutics study enzyme protein streptokinase

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

The Global Protein Therapeutics Market

Credit Card Details

Invoice Details

Table of Contents